Market research
PTI Proteostasis Therapeutics, Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 3M
- P/E ratio
- Not available
- Analyst target
- 5
- Dividend yield
- 0.0%
- Beta
- 1.12
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US74373B1098
- Market cap
- 3M
- P/E ratio
- Not available
- Analyst target
- 5
- Dividend yield
- 0.0%
- Beta
- 1.12
About
About Proteostasis Therapeutics, Inc
Proteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat cystic fibrosis. The company's lead product candidates for the treatment of CF include PTI-801, a cystic fibrosis transmembrane conductance regulator (CFTR) corrector agent; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. It has collaboration agreements with Cystic Fibrosis Foundation, Inc. to research, develop, and commercialize products for the treatment of CF, non-classical CF, and other pulmonary diseases in the United States or the European Union; and Genentech, Inc. for licensing the technology and materials relating to therapeutic small molecule modulators. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics, Inc. in September 2007. Proteostasis Therapeutics, Inc. was founded in 2006 and is headquartered in Boston, Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the PTI discussion.
5 years, 4 months ago
Proteostasis Therapeutics, Inc is currently in a long term downtrend where the price is trading 14.2% below its 200 day moving average.
From a valuation standpoint, the stock is 98.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 16.3.
Proteostasis Therapeutics, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 36.3% to $-8M since the same quarter in the previous year.
Finally, its free cash flow grew by 26.0% to $-8M since the same quarter in the previous year.
Based on the above factors, Proteostasis Therapeutics, Inc gets an overall score of 3/5.